Mene Pangalos, AstraZeneca R&D chief (AstraZeneca via YouTube)
July 15, 2020 10:42 AM EDTUpdated 10:58 AM
R&D
Coronavirus

A day af­ter Mod­er­na vac­cine re­sults, ru­mors swirl of pend­ing As­traZeneca da­ta

Jason Mast

Editor

A day af­ter Mod­er­na and the NIH pub­lished much-an­tic­i­pat­ed da­ta from their Phase I Covid-19 vac­cine tri­al, at­ten­tion is turn­ing to As­traZeneca which, ac­cord­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times